From Systems to Synthetic Biology:

quantitative understandig for rational engineering

Pulmobiotics1.gif

Building on over 10 years of research funded with over 14m € by Spanish and EU grant agencies (details here), we have developed a proprietary microbial engineering and synthetic biology toolbox that underpins a novel live biotherapeutics platform.

 A novel live biotherapeutic platform for treating human lung diseases

 Our platform is based on attenuated lung bacteria able to expose antigens or deliver therapeutic agents in the lung in a controlled, local and continuous manner. It allows engineering of multiple genetic circuits to specifically target and deliver payloads.

Pulmobiotics_pulmon.png
VACCINES
ANTIMICROBIAL ACTIVITY

 Lung Cancer

 Infectious diseases

TISSUE REGENERATION
Tissue.gif

 Chronic obstructive

pulmonary disease

 Infectious diseases

 Cystic Fibrosis

 Infectious diseases

IMMUNE SYSTEM MODULATION
Immune-System.gif

 Asthma

 Lung Cancer

Pulmobiotics_pulmon.png
Antimicrobial.gif

 Pulmobiotics       |       Platform       |      Respiratory diseases     |      Partners       |       Team        |     Contact

 Academic project funding

(awarded to CRG or to consortia participated by CRG)

ERC Proof of Concept grant 335010 “Mico pLung” (2014): 150,000€

 

ERC grant 670216 “MycoChassis” (2015): 2,454,522€

 

EU Horizon 2020 grant 634942 “MycoSynVac” (2015): 8,000,000€

 

EraSynBio “MiniCell” (2015): 200,000€

 

Miguel Servet ISCIII (2017): 121,500€

 

EU Horizon 2020 grant 820699 “BioRoboost” (2018): 1,998,787,50€

 

ERC Proof of Concept grant 825566 “MycoVAP” (2018): 150,000€

 

La Caixa Health “MycoVAP” (2019): 999,528€